Stendra Gets Its 15 Minutes, With New FDA-Approved ED Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Auxilium’s erectile dysfunction drug avanafil was approved by FDA for its ability to work after 15 minutes, a new claim that Auxilium expects will help to differentiate Stendra in a competitive market.
You may also be interested in...
Metuchen Must Correct ED Drug Ads For Adult Sites After US FDA Warning Letter
Promotional campaign for Stendra (avanafil) included "adult sites" as well as the American College of Cardiology's patient-focused magazine; statements that FDA found problematic in the various ads include "get hard and stay hard" and calling the product a "next generation" PDE-5 inhibitor.
Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
With Faster Effects, Vivus Hopes For Quicker Market Penetration For ED Drug Stendra
Dosing instructions to take Stendra (avanafil) 30 minutes before sexual activity give the Vivus drug a shot at the crowded marketplace. With the potential approval of the obesity therapy Qnexa coming up, Vivus could be an attractive take-over target.